LillyDirect – BiotechReality – Information Intelligence System for Biopharma

Eli Lilly and Company declared today that Zepbound (tirzepatide), a popular weight-loss drug, will soon be offered in single-dose vials via LillyDirect Self Pay Pharmacy Solutions in all authorized dosages. The goal of this program is to increase the medication's affordability and accessibility for qualified adults. Regardless of insurance status, all strengths of Zepbound vials will be offered for $499 a month or less under the Zepbound Self Pay Journey Program, with the 2.5 mg starter dose costing $349. Interestingly, this single-dose vial option will also feature the highest permitted doses of Zepbound, which are 12.5 mg and 15 mg, at the $499 monthly pricing range. Obesity is a serious, chronic disease, and access to obesity medications should be treated with the same urgency as other chronic conditions, Lilly was the first company to offer a self-pay solution for an FDA-approved obesity medication, and we continue to work to expand coverage for Zepbound. In the meantime, the availability of the two highest-dose Zepbound vials gives providers and patients another important treatment option. Rhonda Pacheco On July 7, medical professionals can start prescribing the 12.5 mg and 15 mg vials, and patient shipments will start in early August. Regardless of insurance coverage, the program is open to all qualified people who are obese and have a valid prescription. The whole range of Zepbound single-dose vials, including 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, will be available to patients who opt to pay for themselves. Zepbound is a prescription injectable medication designed to help adults who are obese or overweight who have weight-related health issues lose excess weight and keep it off. Additionally, persons with obesity and moderate-to-severe obstructive sleep apnea (OSA) can benefit from it. About ZepboundZepbound is the first and only obesity drug that contains both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonists. Zepbound addresses a root cause of being overweight. It decreases hunger and food intake. Adults who are obese or overweight and have at least one weight-related medical condition can use Zepbound to help them lose weight and keep it off. Zepbound has also received FDA approval to treat obesity and moderate-to-severe obstructive sleep apnea in adults. Zepbound is best used in conjunction with a lower-calorie diet and more exercise. Since Zepbound contains tirzepatide, it should not be taken with any GLP-1 receptor agonist medications or other drugs that also contain tirzepatide. Zepbound's efficacy and safety for use in children are unknown. About LillyDirectA digital health platform called LillyDirect provides disease management tools that facilitate access to high-quality care and individualized information for those with long-term illnesses. Through third-party pharmacy dispensing services, LillyDirect also provides direct home delivery of a few Lilly medications, guaranteeing that patients get their FDA-approved, safe, and effective medications from a reliable and secure source. Every major electronic health record (EHR) system lists LillyDirect as a pharmacy option, and it is available to all U.S. healthcare practitioners who are authorized to dispense Lilly medications. Source: Eli Lilly and Company Last Modified:

Tag: LillyDirect

Lilly to Offer All Approved Doses of Zepbound (tirzepatide) in Single-Dose Vials Through LillyDirect

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment